ANI Pharmaceuticals Q2 adjusted EPS beats on increased volume in specialty areas

ANI Pharmaceuticals

07/08/2026 12:03

Overview
US biopharmaceutical firm's Q2 net revenue grew 25.9% yr/yr to $266.0 mln
Adjusted EPS for Q2 beat analyst expectations
Company authorized $100 mln share repurchase program through May 2029

Outlook
ANI reaffirms 2026 total net revenue guidance of $1.08 bln to $1.14 bln
Company lowers 2026 Cortrophin Gel net revenue outlook to $520 mln-$540 mln from $540 mln-$575 mln
ANI maintains 2026 adjusted non-GAAP EBITDA guidance of $285 mln-$300 mln and EPS of $9.19-$9.69

Result Drivers
CORTROPHIN GEL VOLUME - Co said Q2 growth for Cortrophin Gel was driven primarily by increased volume in specialty areas including Nephrology, Neurology, Ophthalmology, Pulmonology and Rheumatology
GOUT EXPANSION - Co said sales force expansion targeting podiatrists and primary care physicians for Cortrophin Gel in acute gouty arthritis flares was fully operational by end of June, with positive demand metrics
GENERICS LAUNCHES - Co said generics net revenue growth was driven by new product launches and continued strength in partnered generic launch that began in Q3 2025

Company press release: ID:nGNX70ccb5

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EPS
Beat
$2.21
$2.05 (8 Analysts)
Q2 EPS
 
$1.05
 
Q2 Net Income
 
$24.70 mln
 
Q2 Adjusted EBITDA
 
$71.60 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for ANI Pharmaceuticals, Inc. is $105.00, about 27.1% above its August 6 closing price of $82.63
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

Reuters Recommended Reads
Aug 6 - Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
Aug 6 - Viatris raises annual profit forecast on branded drug strength
Aug 6 - Halozyme Q2 revenue jumps 48%, raises 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)